List of Tables
Table 1. Global Bladder Cancer Biologics Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Bladder Cancer Biologics Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Bladder Cancer Biologics Market Competitive Situation by Manufacturers in 2025
Table 4. Global Bladder Cancer Biologics Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Bladder Cancer Biologics Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Bladder Cancer Biologics Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Bladder Cancer Biologics Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Bladder Cancer Biologics Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Bladder Cancer Biologics, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Bladder Cancer Biologics, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Bladder Cancer Biologics, Product Types and Applications
Table 12. Global Key Manufacturers of Bladder Cancer Biologics, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Bladder Cancer Biologics Companies by Tier (Tier 1, Tier 2, Tier 3), based on Bladder Cancer Biologics Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Bladder Cancer Biologics Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Bladder Cancer Biologics Sales by Region (K Units), 2021–2026
Table 18. Global Bladder Cancer Biologics Sales Market Share by Region (2021–2026)
Table 19. Global Bladder Cancer Biologics Sales by Region (K Units), 2027–2032
Table 20. Global Bladder Cancer Biologics Sales Market Share by Region (2027–2032)
Table 21. Global Bladder Cancer Biologics Revenue by Region (US$ Million), 2021–2026
Table 22. Global Bladder Cancer Biologics Revenue Market Share by Region (2021–2026)
Table 23. Global Bladder Cancer Biologics Revenue by Region (US$ Million), 2027–2032
Table 24. Global Bladder Cancer Biologics Revenue Market Share by Region (2027–2032)
Table 25. North America Bladder Cancer Biologics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Bladder Cancer Biologics Sales by Country (K Units), 2021–2026
Table 27. North America Bladder Cancer Biologics Sales by Country (K Units), 2027–2032
Table 28. North America Bladder Cancer Biologics Revenue by Country (US$ Million), 2021–2026
Table 29. North America Bladder Cancer Biologics Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Bladder Cancer Biologics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Bladder Cancer Biologics Sales by Country (K Units), 2021–2026
Table 32. Europe Bladder Cancer Biologics Sales by Country (K Units), 2027–2032
Table 33. Europe Bladder Cancer Biologics Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Bladder Cancer Biologics Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Bladder Cancer Biologics Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Bladder Cancer Biologics Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Bladder Cancer Biologics Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Bladder Cancer Biologics Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Bladder Cancer Biologics Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Bladder Cancer Biologics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Bladder Cancer Biologics Sales by Country (K Units), 2021–2026
Table 42. Latin America Bladder Cancer Biologics Sales by Country (K Units), 2027–2032
Table 43. Latin America Bladder Cancer Biologics Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Bladder Cancer Biologics Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Bladder Cancer Biologics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Bladder Cancer Biologics Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Bladder Cancer Biologics Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Bladder Cancer Biologics Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Bladder Cancer Biologics Revenue by Country (US$ Million), 2027–2032
Table 50. Global Bladder Cancer Biologics Sales (K Units) by Type (2021–2026)
Table 51. Global Bladder Cancer Biologics Sales (K Units) by Type (2027–2032)
Table 52. Global Bladder Cancer Biologics Sales Market Share by Type (2021–2026)
Table 53. Global Bladder Cancer Biologics Sales Market Share by Type (2027–2032)
Table 54. Global Bladder Cancer Biologics Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Bladder Cancer Biologics Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Bladder Cancer Biologics Revenue Market Share by Type (2021–2026)
Table 57. Global Bladder Cancer Biologics Revenue Market Share by Type (2027–2032)
Table 58. Global Bladder Cancer Biologics Price (US$/Unit) by Type (2021–2026)
Table 59. Global Bladder Cancer Biologics Price (US$/Unit) by Type (2027–2032)
Table 60. Global Bladder Cancer Biologics Sales (K Units) by Application (2021–2026)
Table 61. Global Bladder Cancer Biologics Sales (K Units) by Application (2027–2032)
Table 62. Global Bladder Cancer Biologics Sales Market Share by Application (2021–2026)
Table 63. Global Bladder Cancer Biologics Sales Market Share by Application (2027–2032)
Table 64. Global Bladder Cancer Biologics Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Bladder Cancer Biologics Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Bladder Cancer Biologics Revenue Market Share by Application (2021–2026)
Table 67. Global Bladder Cancer Biologics Revenue Market Share by Application (2027–2032)
Table 68. Global Bladder Cancer Biologics Price (US$/Unit) by Application (2021–2026)
Table 69. Global Bladder Cancer Biologics Price (US$/Unit) by Application (2027–2032)
Table 70. AstraZenenca Company Information
Table 71. AstraZenenca Description and Business Overview
Table 72. AstraZenenca Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. AstraZenenca Bladder Cancer Biologics Product
Table 74. AstraZenenca Recent Developments/Updates
Table 75. Bristol-Myers Squibb Company Company Information
Table 76. Bristol-Myers Squibb Company Description and Business Overview
Table 77. Bristol-Myers Squibb Company Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Bristol-Myers Squibb Company Bladder Cancer Biologics Product
Table 79. Bristol-Myers Squibb Company Recent Developments/Updates
Table 80. Chugai Pharmaceutical Company Information
Table 81. Chugai Pharmaceutical Description and Business Overview
Table 82. Chugai Pharmaceutical Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Chugai Pharmaceutical Bladder Cancer Biologics Product
Table 84. Chugai Pharmaceutical Recent Developments/Updates
Table 85. Cold Genesys Company Information
Table 86. Cold Genesys Description and Business Overview
Table 87. Cold Genesys Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Cold Genesys Bladder Cancer Biologics Product
Table 89. Cold Genesys Recent Developments/Updates
Table 90. Eli Lilly Company Information
Table 91. Eli Lilly Description and Business Overview
Table 92. Eli Lilly Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Eli Lilly Bladder Cancer Biologics Product
Table 94. Eli Lilly Recent Developments/Updates
Table 95. Nighthawk Biosciences Company Information
Table 96. Nighthawk Biosciences Description and Business Overview
Table 97. Nighthawk Biosciences Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Nighthawk Biosciences Bladder Cancer Biologics Product
Table 99. Nighthawk Biosciences Recent Developments/Updates
Table 100. Merck & Co Company Information
Table 101. Merck & Co Description and Business Overview
Table 102. Merck & Co Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Merck & Co Bladder Cancer Biologics Product
Table 104. Merck & Co Recent Developments/Updates
Table 105. Mirati Therapeutics Company Information
Table 106. Mirati Therapeutics Description and Business Overview
Table 107. Mirati Therapeutics Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Mirati Therapeutics Bladder Cancer Biologics Product
Table 109. Mirati Therapeutics Recent Developments/Updates
Table 110. OncoGenex Company Information
Table 111. OncoGenex Description and Business Overview
Table 112. OncoGenex Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. OncoGenex Bladder Cancer Biologics Product
Table 114. OncoGenex Recent Developments/Updates
Table 115. Pfizer Company Information
Table 116. Pfizer Description and Business Overview
Table 117. Pfizer Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Pfizer Bladder Cancer Biologics Product
Table 119. Pfizer Recent Developments/Updates
Table 120. Roche Holding Company Information
Table 121. Roche Holding Description and Business Overview
Table 122. Roche Holding Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Roche Holding Bladder Cancer Biologics Product
Table 124. Roche Holding Recent Developments/Updates
Table 125. Spectrum Pharmaceuticals Company Information
Table 126. Spectrum Pharmaceuticals Description and Business Overview
Table 127. Spectrum Pharmaceuticals Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Spectrum Pharmaceuticals Bladder Cancer Biologics Product
Table 129. Spectrum Pharmaceuticals Recent Developments/Updates
Table 130. Taiho Pharmaceutical Company Information
Table 131. Taiho Pharmaceutical Description and Business Overview
Table 132. Taiho Pharmaceutical Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Taiho Pharmaceutical Bladder Cancer Biologics Product
Table 134. Taiho Pharmaceutical Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Bladder Cancer Biologics Distributors List
Table 138. Bladder Cancer Biologics Customers List
Table 139. Bladder Cancer Biologics Market Trends
Table 140. Bladder Cancer Biologics Market Drivers
Table 141. Bladder Cancer Biologics Market Challenges
Table 142. Bladder Cancer Biologics Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
Table 146. Authors List of This Report
List of Figures
Figure 1. Product Picture of Bladder Cancer Biologics
Figure 2. Global Bladder Cancer Biologics Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Bladder Cancer Biologics Market Share by Type: 2025 & 2032
Figure 4. PD-1 Inhibitors Product Picture
Figure 5. CTLA-4 Inhibitors Product Picture
Figure 6. FGFR Inhibitors Product Picture
Figure 7. Others Product Picture
Figure 8. Global Bladder Cancer Biologics Market Value by Application (US$ Million), 2021–2032
Figure 9. Global Bladder Cancer Biologics Market Share by Application: 2025 & 2032
Figure 10. Hospital
Figure 11. Specialty Clinic
Figure 12. Other
Figure 13. Global Bladder Cancer Biologics Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Bladder Cancer Biologics Market Size (US$ Million), 2021–2032
Figure 15. Global Bladder Cancer Biologics Sales (K Units), 2021–2032
Figure 16. Global Bladder Cancer Biologics Average Price (US$/Unit), 2021–2032
Figure 17. Bladder Cancer Biologics Report Years Considered
Figure 18. Bladder Cancer Biologics Sales Share by Manufacturers in 2025
Figure 19. Global Bladder Cancer Biologics Revenue Share by Manufacturers in 2025
Figure 20. Top 5 and Top 10 Global Bladder Cancer Biologics Players: Market Share by Revenue in Bladder Cancer Biologics in 2025
Figure 21. Bladder Cancer Biologics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 22. Global Bladder Cancer Biologics Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 23. North America Bladder Cancer Biologics Sales Market Share by Country (2021–2032)
Figure 24. North America Bladder Cancer Biologics Revenue Market Share by Country (2021–2032)
Figure 25. United States Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Canada Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Europe Bladder Cancer Biologics Sales Market Share by Country (2021–2032)
Figure 28. Europe Bladder Cancer Biologics Revenue Market Share by Country (2021–2032)
Figure 29. Germany Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. France Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. U.K. Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Italy Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Russia Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Asia Pacific Bladder Cancer Biologics Sales Market Share by Region (2021–2032)
Figure 35. Asia Pacific Bladder Cancer Biologics Revenue Market Share by Region (2021–2032)
Figure 36. China Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Japan Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. South Korea Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. India Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Australia Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. China Taiwan Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Southeast Asia Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Latin America Bladder Cancer Biologics Sales Market Share by Country (2021–2032)
Figure 44. Latin America Bladder Cancer Biologics Revenue Market Share by Country (2021–2032)
Figure 45. Mexico Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Brazil Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Argentina Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Colombia Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Middle East and Africa Bladder Cancer Biologics Sales Market Share by Country (2021–2032)
Figure 50. Middle East and Africa Bladder Cancer Biologics Revenue Market Share by Country (2021–2032)
Figure 51. Turkey Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Saudi Arabia Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. UAE Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Global Sales Market Share of Bladder Cancer Biologics by Type (2021–2032)
Figure 55. Global Revenue Market Share of Bladder Cancer Biologics by Type (2021–2032)
Figure 56. Global Bladder Cancer Biologics Price (US$/Unit) by Type (2021–2032)
Figure 57. Global Sales Market Share of Bladder Cancer Biologics by Application (2021–2032)
Figure 58. Global Revenue Market Share of Bladder Cancer Biologics by Application (2021–2032)
Figure 59. Global Bladder Cancer Biologics Price (US$/Unit) by Application (2021–2032)
Figure 60. Bladder Cancer Biologics Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
